Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive daysDOWLATI, Afshin; HOPPEL, Charles L; INGALLS, Stephen T et al.Journal of clinical oncology. 2001, Vol 19, Num 8, pp 2309-2318, issn 0732-183XArticle

A phase II study of rebeccamycin analog NSC 655649 in patients with metastatic colorectal cancerGOEL, Sanjay; WADLER, Scott; HOFFMAN, Anthony et al.Investigational new drugs. 2003, Vol 21, Num 1, pp 103-107, issn 0167-6997, 5 p.Article

Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory propertiesTOLCHER, Anthony W; ECKHARDT, S. Gail; FELTON, Sally et al.Journal of clinical oncology. 2001, Vol 19, Num 11, pp 2937-2947, issn 0732-183XArticle

Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formatsMERCHANT, Joseph; TUTSCH, Kendra; WILDING, George et al.Clinical cancer research. 2002, Vol 8, Num 7, pp 2193-2201, issn 1078-0432Article